Gilead Sciences (GILD)

AI-powered earnings call analysis for Gilead Sciences. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Latest Episode

Q3 2026 Earnings

7:18 • 10/30/2026

Gilead Sciences (GILD) - Q3 2026

0:00

7:18

Speed:

Q3 2026 Earnings

9:04 • 2026/10/30

Gilead Sciences (GILD) - Q3 2026

0:00

9:04

Speed:

Q3 2026 Earnings

10:05 • 30/10/2026

Gilead Sciences (GILD) - Q3 2026

0:00

10:05

Speed:

Q3 2026 Earnings

7:04 • 30/10/2026

Gilead Sciences (GILD) - Q3 2026

0:00

7:04

Speed:

Q3 2026 Earnings

6:03 • 30.10.2026

Gilead Sciences (GILD) - Q3 2026

0:00

6:03

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

7:18

Gilead delivered 16% base business growth driven by HIV and oncology strength, raising 2026 guidance, while facing $1.5B Medicare price headwind to Biktarvy in 2028.

Q2 2026 Earnings

6:26

Gilead delivered 10% base business growth in Q2 2026 driven by HIV, Trodelvy, and Livdelzi, raising full-year HIV guidance to 9-10% and planning two additional launches before year-end.

Q1 2026 Earnings

8:09

Gilead delivered Q1 2026 product sales of $6.9B (+5% YoY) with HIV growth of 10% and Yes2Go blockbuster trajectory, raising full-year guidance $400M while closing transformational acquisitions in oncology and cell therapy.